Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study

BACKGROUND: Eribulin is a nontaxane microtubule inhibitor approved in China for patients with advanced breast cancer who show progression after ⩾2 lines of chemotherapy. The aim of this study was to determine the efficacy and safety profile of eribulin and explore potential predictive factors for th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yannan, Xie, Ning, Li, Wei, Chen, Wenyan, Lv, Zheng, Zheng, Yabing, Sun, Tao, Liu, Jieqiong, Zhang, Jian, Hu, Shihui, Wang, Yajun, Gong, Chengcheng, Li, Yi, Xie, Yizhao, Ge, Rui, Xu, Fei, Wang, Biyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274129/
https://www.ncbi.nlm.nih.gov/pubmed/34290830
http://dx.doi.org/10.1177/17588359211030210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274129/
https://www.ncbi.nlm.nih.gov/pubmed/34290830
http://dx.doi.org/10.1177/17588359211030210

Ejemplares similares